Details

Autor(en) / Beteiligte

• Grunhagen, Dirk J.
• de Wilt, Johannes H. W.
• Graveland, Wilfried J.
• van Geel, Albertus N.
• Eggermont, Alexander M. M.

Titel

The palliative value of tumor necrosis factor α‐based isolated limb perfusion in patients with metastatic sarcoma and melanoma

Ist Teil von

• Cancer, 2006-01, Vol.106 (1), p.156-162

Ort / Verlag

Hoboken: Wiley Subscription Services, Inc., A Wiley Company

Erscheinungsjahr

2006

Quelle

Wiley-Blackwell Journals

Beschreibungen/Notizen

• BACKGROUND Both patients with soft tissue sarcoma (STS) and patients with melanoma have limited treatment possibilities once the tumor has metastasized systemically. In patients with extremity STS or bulky melanoma in‐transit metastases, the local tumor burden may be so problematic that, even in patients with systemically metastasized disease, an amputation may be inevitable. Isolated limb perfusion (ILP) has proven to be an excellent, local, limb‐saving treatment option in patients with locally advanced extremity tumors. In this study, the authors investigated the palliative value of the ILP procedure to avoid amputation in patients who had Stage IV STS and melanoma. METHODS From 1991 to 2003, of 339 tumor necrosis factor α (TNF)‐based ILPs, 51 procedures were performed for either Stage IV STS (n = 37 patients) or Stage IV melanoma (n = 14 patients). All patients underwent an ILP with TNF and melphalan of the upper limb (n = 4 patients) or the lower limb (n = 47 patients) with 26–140 mg melphalan and 2–4 mg TNF. RESULTS The overall response in patients with Stage IV STS was 84%, and their median survival was 12 months after ILP. Limb salvage was achieved in 36 of 37 patients, with 1 patient undergoing amputation due to treatment toxicity. In the patients with Stage IV melanoma, the complete response rate was 43%. All patients with melanoma preserved their limb during a median survival of 7 months. CONCLUSIONS TNF‐based ILP is an excellent procedure that provided tumor control and limb salvage for the short survival of patients with metastasized, very bulky, limb‐threatening tumors of the extremity. Cancer 2006. © 2005 American Cancer Society. Isolated limb perfusion with tumor necrosis factor α and melphalan provided excellent palliation in patients with Stage IV sarcoma and melanoma who had locally disabling tumor burden. Local tumor control and limb salvage were achieved in 98% of this patient population.